Press Releases
Rho names renowned neurologist Andrew Feigin, MD, as Chief Medical Officer
Research Triangle Park, NC – August 5, 2024 – Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, is excited to announce the appointment of Dr. Andrew Feigin, a leading neurologist, as its new Chief Medical Officer (CMO). In this pivotal global role, Dr. Feigin will provide strategic medical and operational expertise across multiple therapeutic areas, ensuring the integrity and safety of Rho’s clinical trials.
Dr. Feigin’s career is marked by groundbreaking contributions to neurology and clinical research. After completing a fellowship in experimental therapeutics, he joined North Shore University Hospital, where he established a renowned clinical trial program for patients with Parkinson’s disease, Huntington’s disease, Tourette syndrome, and other movement disorders. His impressive track record includes serving as the site principal investigator on more than 30 clinical trials, notably spearheading the first phase 1 clinical trial using gene therapy for Parkinson’s disease.
“Andrew’s professional experience is a unique blend of academic research and clinical trial operations,” said Tara Gladwell, president and COO of Rho. “His expertise will be invaluable as our team continues to uncover and advance next-generation therapies, directly benefiting our clients and ultimately improving patient outcomes.”
Before joining Rho, Dr. Feigin led a team that founded a boutique CRO for a rare disease study group, an endeavor that reinforced his passion for impactful clinical research. His desire to amplify his impact on patient lives led him to Rho, where he sees immense potential for collaboration and innovation.
“Strong collaborations between CROs and trusted partners are essential for delivering therapies to patients who need them most,” said Dr. Feigin. “Rho has an incredible team, and I am excited to work with them to strengthen our clinical research program and forge new relationships with the academic world.”
Dr. Feigin graduated from Columbia University Vagelos College of Physicians and Surgeons in 1988. He is a distinguished member of the American Academy of Neurology, the American Neurological Association, the Movement Disorder Society, the Parkinson Study Group, and the Huntington Study Group. His prolific contributions to the field include over 150 peer-reviewed articles and numerous advisory board positions.
With Dr. Feigin on board, Rho is poised to enhance its leadership in clinical research, driving forward innovative solutions and therapies that address some of the most challenging medical conditions.
